Viewing nowCombinationCebiroten Tablet 5/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.

MFDS item code 201405504 · Approved 2014.11.25 · Insurance code 646003870
Treatment of essential hypertension not controlled by monotherapy
Amlodipine or olmesartan medoxomil is medication used when blood pressure is not adequately controlled with monotherapy in patients with essential hypertension. These medications help lower blood pressure and reduce the risk of cardiovascular complications. They are used to effectively manage blood pressure and improve health through consistent use.
Administer 1 tablet of this medicine once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ○ Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
○ Children: The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.
This medication may cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergies to its components, severe liver impairment, severe aortic stenosis, biliary obstruction, patients undergoing renal dialysis, those in a state of shock, and certain diabetes patients. Hypotension may occur in patients with fluid or electrolyte depletion, so monitoring should be done closely upon initial administration. Rapid vascular dilation may lead to hypotension; hence, caution should be taken in patients especially with heart valve diseases. Careful use is required in patients with heart failure as well as in patients with renal impairment. For patients with impaired liver function, the metabolism of this drug may be slowed down, requiring careful administration. Side effects such as dizziness, headache, hypotension, cough, digestive disorders, and skin rash may occur during treatment; if unusual symptoms arise, please consult a physician. This medication may pose risks to the fetus during pregnancy; therefore, those planning a pregnancy or currently pregnant must consult a physician. During breastfeeding, this medication may be transmitted through breast milk and affect the baby, so it is advised to discontinue breastfeeding or stop taking the medication. Safety and efficacy have not been established in children under 18 years of age and is not recommended. Elderly patients may have reduced liver and renal function, so it is advised to start at a lower dose and closely monitor their condition. Overdose may result in hypotension and arrhythmias, so immediate medical attention should be sought if symptoms appear. This medication may interact with other drugs; therefore, it is essential to inform your physician or pharmacist of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air and moisture. It is best to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature.
Pale yellow round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.